Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)
Patel, V., Mcphail, M.J.W., Zamalloa, A., Støy, S., Vijay, G.M., Huang, X., Rogers, G., Choo, J., Edwards, L., Gray, E., Woodhouse, C., Gencer, S., Coen, M., Wendon, J., Bruce, K., Shawcross, D.Volume:
68
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(18)30432-X
Date:
April, 2018
File:
PDF, 117 KB
english, 2018